Indeed, my bad, all of the Cytodyn's Intellectual
Post# of 148216
This is the Security Agreement from the first $25 million financing executed on about June 30, 2020:
https://www.cytodyn.com/investors/sec-filings...dex102.htm
This seems quite remarkable to me.
The noteholder gets the inventory, the factory, and all the gadgets in the factory, but DOES NOT get the Intellectual Property needed to create the product.
Am I just wrong that the IP is required to manufacture the product?
Maybe since Samsung already has an established manufacturing line, then Samsung is already in possession of any and all Intellectual Property needed to manufacture leronlimab. Samsung already has the amino acid sequence needed to build the antibody.